Skip to main content
. Author manuscript; available in PMC: 2026 Jul 22.
Published in final edited form as: Trends Pharmacol Sci. 2025 Jul 22;46(8):722–737. doi: 10.1016/j.tips.2025.06.008

Figure 3: Tumors with LKB1 deficiency have a distinct microenvironment characterized by ECM remodeling and an immunosuppressive TME.

Figure 3:

Schematic summarizing recent findings. A) Compared to LKB1 proficient tumors (right), LKB1 deficient tumors (left) exhibit reduced T cell infiltration, enhanced abundance of immunosuppressive cells and inflammatory cytokines, and increased ECM deposition. B) Combination therapies that reverse LKB1-specific TME characteristics to enhance anti-tumor immune response. FAKi, FAK inhibition